| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.
|
Clin Cancer Res
|
2008
|
2.27
|
|
2
|
Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor.
|
Mol Cancer Ther
|
2010
|
1.94
|
|
3
|
Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production.
|
Blood
|
2002
|
1.84
|
|
4
|
Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
|
Cancer Res
|
2006
|
1.79
|
|
5
|
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
|
Clin Cancer Res
|
2003
|
1.61
|
|
6
|
Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).
|
Proc Natl Acad Sci U S A
|
2003
|
1.11
|
|
7
|
Polyglutamine repeat length-dependent proteolysis of huntingtin.
|
Neurobiol Dis
|
2002
|
1.00
|
|
8
|
Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes.
|
J Cardiovasc Pharmacol
|
2011
|
0.96
|
|
9
|
Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant.
|
Regul Toxicol Pharmacol
|
2002
|
0.96
|
|
10
|
SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth.
|
Blood
|
2006
|
0.96
|
|
11
|
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
|
Blood
|
2005
|
0.95
|
|
12
|
R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells.
|
Cancer Chemother Pharmacol
|
2006
|
0.84
|
|
13
|
Determination of derivatized l-alanosine in plasma by liquid chromatography-tandem mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2004
|
0.75
|
|
14
|
Circadian pharmacology of L-alanosine (SDX-102) in mice.
|
Mol Cancer Ther
|
2006
|
0.75
|
|
15
|
Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro.
|
Invest New Drugs
|
2007
|
0.75
|
|
16
|
SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma.
|
Arch Pharm (Weinheim)
|
2007
|
0.75
|